Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731–40.

Article  PubMed  CAS  Google Scholar 

Brandsema JF, Darras BT. Dystrophinopathies. Semin Neurol. 2015;35:369–84.

Article  PubMed  Google Scholar 

Cappa R, Brandsema JF. Dystrophinopathies and the Limb-Girdle Muscular Dystrophies. Pract Neurol. 2023;49–52.

Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primer. 2021;7:1–19.

Article  Google Scholar 

Johnson R, Otway R, Chin E, Horvat C, Ohanian M, Wilcox JAL, et al. DMD-Associated Dilated Cardiomyopathy: Genotypes, Phenotypes, and Phenocopies. Circ Genomic Precis Med. 2023;16:421–30.

Article  CAS  Google Scholar 

Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2024 Dec 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1119/

Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919–28.

Article  PubMed  CAS  Google Scholar 

Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. Lancet Lond Engl. 2019;394:2025–38.

Article  Google Scholar 

Wilson DGS, Tinker A, Iskratsch T. The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction. Commun Biol. 2022;5:1–18.

Article  Google Scholar 

Kariyawasam D, D’Silva A, Mowat D, Russell J, Sampaio H, Jones K, et al. Incidence of Duchenne muscular dystrophy in the modern era; an Australian study. Eur J Hum Genet. 2022;30:1398–404.

Article  PubMed  PubMed Central  Google Scholar 

Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M, Crowther M. Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink. Brain Behav. 2023;13:e3331.

Article  PubMed  PubMed Central  Google Scholar 

McDonald CM, Henricson EK, Abresch RT, Han JJ, Escolar DM, Florence JM, et al. The cooperative international neuromuscular research group Duchenne natural history study–a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48:32–54.

Article  PubMed  PubMed Central  Google Scholar 

Nakamura A, Matsumura T, Ogata K, Mori-Yoshimura M, Takeshita E, Kimura K, et al. Natural history of Becker muscular dystrophy: a multicenter study of 225 patients. Ann Clin Transl Neurol. 2023;10:2360–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ho R, Nguyen M-L, Mather P. Cardiomyopathy in becker muscular dystrophy: Overview. World J Cardiol. 2016;8:356–61.

Article  PubMed  PubMed Central  Google Scholar 

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.

Article  PubMed  Google Scholar 

McDonald CM, Signorovitch J, Mercuri E, Niks EH, Wong B, Fillbrunn M, et al. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials. PLoS ONE. 2024;19:e0304099.

Article  PubMed  PubMed Central  CAS  Google Scholar 

GeoS M. On the Pathology of Pseudo-Hypertrophic Muscular Paralysis, with Remarks on a So-Called Degeneration of the Nervous System. Glasg Med J. 1884;22:81–106.

Google Scholar 

Bell C. The nervous system of the human body : embracing the papers delivered to the Royal Society on the subject of the nerves [Internet]. London : Longman, Rees, Orme, Brown, and Green; 1830 [cited 2024 Dec 8]. Available from: https://archive.hshsl.umaryland.edu/handle/10713/3152

Ryan WB. Pseudo-Hypertrophic Muscular Paralysis: Read before the Indiana State Medical Society. J Am Med Assoc. 1888;XI:807–10.

Article  Google Scholar 

Tyler KL. Origins and early descriptions of “Duchenne muscular dystrophy.” Muscle Nerve. 2003;28:402–22.

Article  PubMed  Google Scholar 

Becker PE. Kiener F [A new x-chromosomal muscular dystrophy]. Arch Psychiatr Nervenkrankh Ver Mit Z Gesamte Neurol Psychiatr. 1955;193:427–48.

CAS  Google Scholar 

Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature. 1986;323:646–50.

Article  PubMed  CAS  Google Scholar 

Juan-Mateu J, González-Quereda L, Rodriguez MJ, Jou C, Nascimento A, Jimenez-Mallebrera C, et al. Isolated cognitive abnormalities associated to DMD mutations. Neuromuscul Disord. 2013;23:753.

Article  Google Scholar 

Marti P, Muelas N, Mayordomo F, Azorin I, Blanch S, Millan C, et al. Long-term follow up of patients with dystrophin deficiency and isolated hyperCKemia. Neuromuscul Disord. 2015;25:S198–9.

Article  Google Scholar 

Kamdar F, Garry DJ. Dystrophin-Deficient Cardiomyopathy. J Am Coll Cardiol. 2016;67:2533–46.

Article  PubMed  CAS  Google Scholar 

McDonald CM, Wu S, Gulati S, Komaki H, Escobar RE, Kostera-Pruszczyk A, et al. Safety and efficacy of ataluren in nmDMD patients from study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (PL5.001). Neurology. 2023;100:2374.

Article  Google Scholar 

McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, et al. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. J Neuromuscul Dis. 2021;8:989–1001.

Article  PubMed  PubMed Central  Google Scholar 

Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87:2123–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, et al. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther. 2022;32:29–39.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, McDonald CM, et al. Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. J Neuromuscul Dis. 2023;10:439–47.

Article  PubMed  PubMed Central  Google Scholar 

Iannaccone S, Phan H, Straub V, Muntoni F, Wolf D, Malhotra J, et al. Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: Interim results from the Phase 3 ESSENCE trial. Neuromuscul Disord. 2022;32:S102.

Article  Google Scholar 

Dang UJ, Damsker JM, Guglieri M, Clemens PR, Perlman SJ, Smith EC, et al. Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy. Neurology. 2024;102:e208112.

Article  PubMed  PubMed Central  Google Scholar 

Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332–41.

Article  PubMed  CAS  Google Scholar 

Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23:393–403.

Article  PubMed  CAS  Google Scholar 

Mitchell R, Frederick NE, Holzman ER, Agobe F, Allaway HCM, Bagher P. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy. Am J Physiol Heart Circ Physiol. 2021;321:H52–8.

Article  PubMed  CAS  Google Scholar 

McDonald CM, Marbán E, Hendrix S, Hogan N, Ruckdeschel Smith R, Eagle M, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2022;399:1049–58.

Article  CAS